{
    "organizations": [],
    "uuid": "b6083f777a03389bc68177f63d41b9903b428d46",
    "author": "",
    "url": "https://www.reuters.com/article/brief-vertex-receives-eu-approval-for-or/brief-vertex-receives-eu-approval-for-orkambi-idUSASM000HYX",
    "ord_in_thread": 0,
    "title": "BRIEF-Vertex Receives EU Approval For Orkambi",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "January 10, 2018 / 2:48 PM / in 12 minutes BRIEF-Vertex Receives EU Approval For Orkambi Reuters Staff 1 Min Read \nJan 10 (Reuters) - Vertex Pharmaceuticals Inc: \n* VERTEX RECEIVES EU APPROVAL FOR ORKAMBIÂ® (LUMACAFTOR/IVACAFTOR) IN CHILDREN WITH CYSTIC FIBROSIS AGES 6-11 WITH TWO COPIES OF THE F508DEL MUTATION Source text for Eikon: Further company coverage:",
    "published": "2018-01-10T16:47:00.000+02:00",
    "crawled": "2018-01-10T17:05:11.009+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "january",
        "pm",
        "minute",
        "receives",
        "eu",
        "approval",
        "orkambi",
        "reuters",
        "staff",
        "min",
        "read",
        "jan",
        "reuters",
        "vertex",
        "pharmaceutical",
        "inc",
        "vertex",
        "receives",
        "eu",
        "approval",
        "child",
        "cystic",
        "fibrosis",
        "age",
        "two",
        "copy",
        "f508del",
        "mutation",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}